AlphAIAlphAI — Financial news for AI agents
thepharmaletter.comSEP 121 min read

FDA approves Pharming’s Joenja for children

The FDA approved Pharming's Joenja for treating children aged 4-11 with APDS, a rare immunodeficiency. The Dutch biopharma firm (PHARM) expects the new pediatric doses to be available in the US in October. This marks the first FDA-approved treatment for this age group with APDS.

Original reporting
thepharmaletter.com
Published Sep 12, 2026, 5:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 12, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
FDA approves Pharming’s Joenja for children — source image
Source · thepharmaletter.com
Decision brief

The 30-second read

High
01

Why it matters

Regulatory approval expands addressable market and may accelerate revenue growth.

02

Market read

First pediatric APDS therapy in the U.S., likely to move Pharming stock.

03

What to watch

Potential reimbursement challenges and limited patient pool could temper upside.

Relevance 8/10Novelty 9/10Timing: today

Background

Pharming is a Dutch biotech focused on rare immunodeficiency disorders.

Market effects

Sector

strengthens biotech/rare disease sector sentiment

Regional

positive for European biotech stocks

Global

adds to overall pharma pipeline optimism

Counterpoint

What could challenge this read

Market may have priced in approval already; execution risk remains.

Key entities

  • Company
    Pharming

    Dutch biopharma developing Joenja (leniolisib).

  • Regulator
    FDA

    U.S. Food and Drug Administration granting approval.

Read at source← All news

Related articles

AUG 13
$PHARMed

Pharming Launches Joenja In Japan For APDS

Pharming Group (PHAR) said Joenja (leniolisib) has started commercial sales in Japan for APDS patients aged 4 and older, after inclusion on Japan’s NHI price list. The drug is an oral PI3K delta inhibitor approved based on a Phase III trial and supported by long-term extension data. OrphanPacific is the local partner.

rttnews.com3 min
JUL 30
$PHARHigh

Pharming Group N.V. (PHAR): Financial results for Q2 2026

Pharming Group N.V. (PHAR) furnished an SEC Form 6-K — earnings release. Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., dated July 30, 2026. 1 EXHIBIT INDEX Exhibit No. Description 99.1 Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja mom

SEC EDGAR 6-K2 min
JUL 30
$PHARMedAI 8/10

Pharming Group N.V.: Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader ther

Pharming Group N.V. reported Q2 2026 total revenues of US$90.2m, down 3% year over year. RUCONEST revenue was US$72.3m, down 10% YoY, while Joenja (leniolisib) revenue rose to US$17.9m, up 40% YoY. Q2 operating profit fell to US$1.3m. The company revised 2026 revenue guidance to US$375m-395m and operating expense guidance to US$315m-320m.

finanznachrichten.de7 min
JUN 4
$PHARMedAI 9/10

Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

Pharming said the U.S. FDA accepted its resubmitted supplemental NDA for Joenja (leniolisib) to treat children ages 4–11 with APDS. After a Jan. 30, 2026 CRL and a March 26 Type A meeting, the sNDA seeks approval for 40 mg and 50 mg twice daily for patients ≥27 kg, with FDA requesting additional batch-testing analytical data. The PDUFA target action date is Oct. 24, 2026. A separate sNDA for lower-weight patients is planned for the second half of 2026.

manilatimes.net4 min